ArticlePloS one2012
EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Oncolytic herpes simplex viruses designed for targeted treatment of EGFR-bearing tumors.Molecular therapy. Oncology · 2024Article
- Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.Journal of cellular physiology · 2020Article
- Tissue transglutaminase 2 regulates tumor cell tensional homeostasis by increasing contractility.Journal of cell science · 2020Article
- Article
- Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains.Oncogene · 2020Article
- Pleiotropic Role of Tenascin-C in Central Nervous System Diseases: From Basic to Clinical Applications.Frontiers in neurology · 2020Review
- Multi-Cell Type Glioblastoma Tumor Spheroids for Evaluating Sub-Population-Specific Drug Response.Frontiers in bioengineering and biotechnology · 2020Article
- Article
- The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.Cellular oncology (Dordrecht, Netherlands) · 2019Article
- Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma.International journal of molecular sciences · 2018Review
- Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma.Advanced healthcare materials · 2017Article
- The Impact of Non-Lethal Single-Dose Radiation on Tumor Invasion and Cytoskeletal Properties.International journal of molecular sciences · 2017Article
- Precision knockdown of EGFR gene expression using radio frequency electromagnetic energy.Journal of neuro-oncology · 2017Article
- [Quantitative analysis of enhanced MRI features for predicting epidermal growth factor receptor gene amplification in glioblastoma multiforme with radiomic method].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2017Article
- An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis.Oncogene · 2015Article
- Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis.Journal of pharmacokinetics and pharmacodynamics · 2015Article
- Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma.Cell communication and signaling : CCS · 2015Review
- Role of tenascins in the ECM of gliomas.Cell adhesion & migration · 2015Review
- ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways.Journal of molecular medicine (Berlin, Germany) · 2014Article
- Unraveling the cytotoxic potential of Temozolomide loaded into PLGA nanoparticles.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014Article
Corrections and comments
- Correction · 2020-02-27Error in Text · Original Data and/or Images not Provided and/or not Available · Upgrade/Update of Prior Notice(s) ·
- Retraction · 2019-09-03Concerns/Issues about Data · Duplication of/in Image · Error in Cell Lines/Tissues · Investigation by Journal/Publisher · Original Data and/or Images not Provided and/or not Available · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enforced EGFR activation upon gene amplification and/or mutation is a common hallmark of malignant glioma. Small molecule EGFR tyrosine kinase inhibitors, such as erlotinib (Tarceva), have shown some activity in a subset of glioma patients in recent trials, although the reported data on the cellular basis of glioma cell responsiveness to these compounds have been contradictory. Here we have used a panel of human glioma cell lines, including cells with amplified or mutant EGFR, to further characterize the cellular effects of EGFR inhibition with erlotinib. Dose-response and cellular growth assays indicate that erlotinib reduces cell proliferation in all tested cell lines without inducing cytotoxic effects. Flow cytometric analyses confirm that EGFR inhibition does not induce apoptosis in glioma cells, leading to cell cycle arrest in G(1). Interestingly, erlotinib also prevents spontaneous multicellular tumour spheroid growth in U87MG cells and cooperates with sub-optimal doses of temozolomide (TMZ) to reduce multicellular tumour spheroid growth. This cooperation appears to be schedule-dependent, since pre-treatment with erlotinib protects against TMZ-induced cytotoxicity whereas concomitant treatment results in a cooperative effect. Cell cycle arrest in erlotinib-treated cells is associated with an inhibition of ERK and Akt signaling, resulting in cyclin D1 downregulation, an increase in p27(kip1) levels and pRB hypophosphorylation. Interestingly, EGFR inhibition also perturbs Rho GTPase signaling and cellular morphology, leading to Rho/ROCK-dependent formation of actin stress fibres and the inhibition of glioma cell motility and invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.